Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France
NCT06421311
·
clinicaltrials.gov ↗
TERMINATED
Status
176
Enrollment
INDUSTRY
Sponsor class
Stopped
Business objectives have changed
Conditions
Urothelial Carcinoma
Interventions
DRUG:
nivolumab
Sponsor
Bristol-Myers Squibb